The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy

By M. Scaltriti, J. Baselga. Clinical Cancer Research, 2006

906 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Targets of curcumin (2011, background): “The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is an integral plasma membrane protein kinase that is composed of a cysteine-rich extracellular ligandbinding domain, a hydrophobic transmembrane domain, and intracellular C-terminal tails containing tyrosine kinase function and sev”
The epidermal growth factor receptor family: Biology driving targeted therapeutics (2008, background): “Multiple signal transduction pathways lie downstream of activated EGFRs and have been reviewed elsewhere [2,37] (Fig.”
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer (2007, background): “The EGFR family consists of four transmembrane receptors: EGFR (HER1/erbB-1), HER2 (erbB-2/neu), HER3 (erbB-3) and HER4 (erbB-4) (Mendelsohn and Baselga, 2006; Scaltriti and Baselga, 2006).”
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come (2016, background): “proliferation, angiogenesis, invasion, and metastasis (Scaltriti and Baselga, 2006).”
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. (2010, background): “Human epidermal receptor-2 (HER-2) is reported to be expressed in 14–91% of patients with breast cancer [49,50].”